Hybridoma cell line (OKT3), is a cell line used to produce IgG2a monoclonal antibodies against CD3 antigen of human T lymphocyte cells. OKT3 is a monoclonal antibody targeted at the CD3 receptor located on the surface of T cells. Being approved by the FDA in 1985, it is also an immunosuppressant drug given to reduce acute rejection in patients with organ transplants, making it the first monoclonal antibody to be approved anywhere as a drug for humans.
Specifications
Catalog Number:
KP-3001
Antibodies Name:
Human-CD3-antibody-OKT3
Host Cell Line:
EXPI-CHO
Target:
CD3
Species Reactivity:
Human
Application:
ELISA | FACS | Function assay | KD
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
1.Pauline Wimberger Wei Xiang &Doris Mayr et al. Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in primary ovarian cancer samples by an EP-CAM-/CD3-bispecific antibody. IJC. Volume105, Issue2(2003).
